Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Key Highlights
- ➤Five abstracts accepted for Aligos (ALGS) presentations at The Liver Meeting 2026
- ➤Pevifoscorvir sodium study reports immune-modulatory effects in HBeAg-positive chronic HBV patients
- ➤Pevifoscorvir sodium reduced HBsAg levels below 3000 IU/mL after long-term treatment
- ➤ALG-170675 shows efficacy, pharmacokinetics, and safety in preclinical HBV models
- ➤ALG-215007 potently inhibited hepatitis Delta virus replication preclinically
Expert Statements
Lung-Yi Loey Mak, Clinical Assistant Professor at The University of Hong Kong
“Immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients with chronic hepatitis B infection”
Man-Fung Yuen, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
“Pevifoscorvir Sodium Reduces HBsAg Levels to < 3000 IU/mL in HBeAg Positive Subjects with Chronic HBV Infection Following Long-Term On-Study Treatment”
Andreas Jekle, Presenter
“Pevifoscorvir Sodium (CAM-E) is Superior to Nucleos(t)ide Analogs in Suppressing Hepatitis B Virus Double-stranded Linear DNA In Vitro”
Jin Hong, Presenter
“The potentially best-in-class HBV ASO ALG-170675 demonstrates a favourable preclinical profile: efficacy in an AAV-HBV mouse model, pharmacokinetics and safety in mouse and monkey”
Kellan Passow, Presenter
“Potent Inhibition of Hepatitis Delta Virus Replication by the Antisense Oligonucleotide ALG-215007”
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting(® )2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.
Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection
Get started
Create a free account to read the full story.